Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of eczema, known as atopic dermatitis, is characterized by persistent ...